News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Landmark Pfizer Inc. (PFE) Vaccine Study Could Change Medicine And Boost Stock


2/24/2014 8:13:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfizer just announced in a press release that an 85,000-patient study conducted in the Netherlands shows that its Prevnar 13 vaccine prevents pneumonia and invasive bacterial infection in adults aged 65 and older. The news has the potential to dramatically increase the number of adults who are vaccinated against the pneumococcus bacteria. Both Prevnar 13 and an older vaccine from Merck are approved for this use by the Food and Drug Administration, but use of the vaccines has been limited because there was not proof as to how well the vaccine prevents people from becoming sick.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES